This competing renewal application represents the merger of two of the most productive nodes of the NIDA Clinical Trials Network - the New England Node, led by Yale University's Kathleen Carroll, Ph.D., and the Northern New England Node, led by Harvard University's Roger Weiss, M.D.- to form the New England Consortium Node (NECN). Drs. Carroll and Weiss will both be PIs of the NECN, using the multiple PI mechanism. This proposal to combine these two nodes enhances the strengths of each node by providing broader and deeper scientific expertise and greater diversity of community treatment programs (CTPs). Beyond capitalizing on economies of scale for prudent use of CTN resources, our nodes provide an ideal opportunity for integration, based on 1) geographical proximity, 2) complementary scientific expertise, 3) a history of collaboration, and 4) complementary CTP patient populations. Since joining the CTN, the New England and Northern NE Nodes have been highly productive in all key areas of CTN performance: 1) trial leadership, 2) scientific productivity, including publications and presentations, 3) administrative leadership, 4) excellent trial performance, and 5) dissemination of findings from CTN trials to CTPs. NECN personnel have led 4 highly successful and productive CTN trials and have been leaders in disseminating findings of CTN-tested interventions to the wider drug abuse treatment community, both in New England and nationally. Administrative leadership is exemplified by election by our CTN peers to virtually all major CTN leadership positions. NECN CTPs have adopted a number of evidence- based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the New England and Northern NE Nodes in their current funding periods and their entire tenure in the CTN. The proposal also describes plans for integration of these two highly successful nodes into a seamlessly integrated combined node. Finally, the proposal will use a number of potential research ideas that are consistent with the evolving mission of the CTN.

Public Health Relevance

The CTN does clinically relevant drug abuse research in real-world settings;the structure of the CTN is designed to maximize the likelihood that treatments found to be successful in CTN trials are then disseminated widely to CTPs nationally, which should help improve the overall treatment of drug abuse and comorbid conditions nationwide.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA015831-09S2
Application #
8236002
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2002-09-30
Project End
2015-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
9
Fiscal Year
2011
Total Cost
$500,980
Indirect Cost
Name
Mclean Hospital
Department
Type
DUNS #
046514535
City
Belmont
State
MA
Country
United States
Zip Code
02478
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Paris, Manuel; Silva, Michelle; Añez-Nava, Luis et al. (2018) Culturally Adapted, Web-Based Cognitive Behavioral Therapy for Spanish-Speaking Individuals With Substance Use Disorders: A Randomized Clinical Trial. Am J Public Health 108:1535-1542
Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209
Montgomery, LaTrice; Carroll, Kathleen M (2017) Comparable efficacy of behavioral and pharmacological treatments among African American and White cocaine users. J Ethn Subst Abuse 16:445-459
Campbell, Aimee N C; Montgomery, L; Sanchez, Katherine et al. (2017) Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders. J Ethn Subst Abuse 16:460-478
Lee, J D; Tofighi, B; McDonald, R et al. (2017) Acceptability and effectiveness of a web-based psychosocial intervention among criminal justice involved adults. Health Justice 5:3
Fitzmaurice, Garrett M; Lipsitz, Stuart R; Weiss, Roger D (2017) Statistical considerations in the choice of endpoint for drug use disorder trials. Drug Alcohol Depend 181:219-222
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80

Showing the most recent 10 out of 135 publications